Adaptimmune Therapeutics (ADAP)

NASDAQ: ADAP · Real-Time Price · USD

0.28

0.00 (1.19%)

At close: May 01, 2025, 3:59 PM

0.28

-0.61%

After-hours: May 01, 2025, 07:48 PM EDT

Adaptimmune Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	178.03M	60.28M	27.15M	6.15M	3.96M	1.12M	59.51M	37.83M	14.2M
Cost of Revenue	70K	9.86M	127.73M	111.09M	91.57M	97.5M	n/a	n/a	n/a
Gross Profit	177.96M	50.42M	-100.58M	-104.94M	-87.61M	-96.38M	59.51M	37.83M	14.2M
Operating Income	-68.76M	-138.04M	-163.97M	-162.25M	-133.41M	-139.77M	-82.36M	-80.66M	-72.8M
Interest Income	6.6M	5.96M	1.54M	1.09M	2.31M	2.77M	2.85M	2.23M	1.11M
Pretax Income	-67.24M	-112.53M	-162.96M	-157.3M	-129.93M	-136.92M	-95.02M	-69.69M	-70.69M
Net Income	-70.81M	-113.87M	-165.46M	-158.09M	-130.09M	-137.16M	-95.51M	-70.14M	-71.58M
Selling & General & Admin	81.31M	71.81M	63.39M	57.3M	45.8M	43.39M	43.6M	31.11M	23.21M
Research & Development	149.06M	126.51M	127.73M	111.09M	91.57M	97.5M	98.27M	87.39M	63.79M
Other Expenses	16.35M	n/a	-536K	3.85M	1.16M	75K	-15.5M	8.74M	1M
Operating Expenses	246.72M	188.42M	191.11M	168.4M	137.36M	140.89M	141.87M	118.49M	87M
Interest Expense	3.35M	n/a	n/a	n/a	n/a	n/a	376K	2.23M	n/a
Selling & Marketing Expenses	506K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	246.79M	198.28M	191.11M	168.4M	137.36M	140.89M	141.87M	118.49M	87M
Income Tax Expense	3.58M	1.34M	2.5M	791K	162K	242K	497K	451K	892K
Shares Outstanding (Basic)	252.3M	201.07M	161.21M	155.81M	142.46M	104.97M	97.39M	87.94M	70.79M
Shares Outstanding (Diluted)	252.3M	201.07M	161.21M	155.81M	142.46M	104.97M	97.39M	87.94M	70.79M
EPS (Basic)	-0.28	-0.57	-1.02	-1.02	-0.9	-1.32	-0.96	-0.78	-1.02
EPS (Diluted)	-0.28	-0.57	-1.02	-1.02	-0.9	-1.32	-0.96	-0.78	-1.02
EBITDA	-52.66M	-128.2M	-155.59M	-155.68M	-125.81M	-131.76M	-74.56M	-75.24M	-69.51M
EBIT	-63.89M	-138.04M	-161.67M	-162.25M	-133.41M	-139.77M	-82.36M	-80.66M	-72.8M
Depreciation & Amortization	11.23M	9.84M	6.07M	6.57M	7.65M	8.04M	7.81M	5.42M	3.29M